Highest-materiality recent filing
Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027
Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M
FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH
In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR
Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.
Upfront $40M cash + 1.9M Lyell shares; up to $820M in milestones plus tiered royalties up to 10% on US net sales.
Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
Lyell Immunopharma CFO Charles Newton resigns effective Oct 31, 2025
Charles Newton resigns as CFO and principal financial/accounting officer, effective October 31, 2025.
Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share
Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.
Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL
In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.
Max materiality 0.85 · Median 0.68 · Most common event other_material